Total item
Cart Subtotal
$0.00 mTOR
| Catalog No. | Inhibitor Name | mTOR | mTORC1 | mTORC2 | Other Targets |
|---|---|---|---|---|---|
| A10133 | Dactolisib | *** | p110α,p110γ,p110δ | ||
| A10782 | Rapamycin | **** | |||
| A10374 | Everolimus | *** | |||
| A10114 | AZD8055 | **** | DNA-PK,PI3Kδ,PI3Kα | ||
| A10906 | Temsirolimus | * | |||
| A10726 | PI-103 | * | p110α,p110δ,p110β | ||
| A10505 | KU-0063794 | ** | ** | ||
| A10746 | Torkinib | ** | p110δ,PDGFR,DNA-PK | ||
| A10295 | Ridaforolimus | **** | |||
| A11461 | INK 128 | **** | PI3Kα,PI3Kγ,PI3Kδ | ||
| A10997 | Voxtalisib Analogue | * | PI3Kγ,PI3Kα,PI3Kδ | ||
| A11587 | Torin 1 | *** | *** | ** | DNA-PK,p110γ,C2α |
| A11035 | Omipalisib | **** | **** | p110α,p110δ,p110γ | |
| A11056 | OSI-027 | *** | * | * | PI3Kγ,DNA-PK,PI3Kα |
| A11024 | PF-04691502 | ** | PI3Kδ,PI3Kα,PI3Kγ | ||
| A11023 | Apitolisib | * | p110α,p110δ,p110γ | ||
| A10438 | GSK1059615 | ** | PI3Kα,PI3Kβ,PI3Kδ | ||
| A11079 | Gedatolisib | **** | PI3Kα,PI3Kγ | ||
| A10989 | WYE-354 | *** | PI3Kα,PI3Kγ | ||
| A11303 | Vistusertib | *** | P-Akt (S473),pS6 (S235/236) | ||
| A11586 | Torin 2 | **** | ATM,ATR,DNA-PK | ||
| A11038 | WYE-125132 | **** | |||
| A11207 | PP121 | ** | PDGFR,Hck,VEGFR | ||
| A11187 | WYE-687 | *** | PI3Kα,PI3Kγ,p38α | ||
| A11169 | CH5132799 | * | PI3Kα,PI3Kγ,PI3Kβ | ||
| A11188 | WAY-600 | ** | PI3Kα,PI3Kγ | ||
| A13328 | ETP-46464 | **** | ATR,DNA-PK,PI3Kα | ||
| A11443 | GDC-0349 | *** | PI3Kα | ||
| A12395 | XL388 | ** | ** | * | CYP2C9,CYP3A4 |
| A13078 | CC-223 | ** | cFMS,FLT4,DNA-PK | ||
| A16276 | Voxtalisib | * | PI3Kγ,PI3Kα,PI3Kδ | ||
| A11950 | Zotarolimus | *** | |||
| A10389 | Tacrolimus | ||||
| A11162 | BGT226 | PI3Kα,PI3Kγ,PI3Kβ | |||
| A10693 | Palomid 529 | ||||
| A10210 | Chrysophanic Acid | EGFR | |||
| A11537 | QL-IX-55 | ||||
| A12480 | VS-5584 | **** | PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ | ||
| A12704 | SF1126 | PI3K | |||
| A12935 | PF-04979064 | **** | PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ, Akt | ||
| A14432 | GNE-493 | *** | PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ | ||
| A15175 | mTOR inhibitor (mTOR-IN-1) | *** | |||
| A15508 | MHY1485 | ||||
| A16126 | LY3023414 | PI3Kα, Akt1, DNA-PK |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
QL-IX-55
Catalog No. A11537 mTORC1/2 inhibitorQL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively. Learn More -
WYE-354
Catalog No. A10989 mTOR InhibitorWYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2. It is a much weaker inhibitor of PI3K α (IC50 = 1026 nM) and other kinases. Learn More -
FK-506 (Tacrolimus)
Catalog No. A10389 mTOR inhibitorFK-506 is an immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It reduces interleukin-2 (IL-2) production by T-cells. Learn More -
AZD2014 (Vistusertib)
Catalog No. A11303 mTORC1/2 inhibitorAZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor. Learn More -
Torin 2
Catalog No. A11586 mTOR inhibitorTorin 2 is a potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Learn More -
AZD8055
Catalog No. A10114 mTOR InhibitorAZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. Learn More -
VS-5584
Catalog No. A12480 PI3K/mTOR inhibitorVS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Learn More -
mTOR inhibitor (mTOR-IN-1)
Catalog No. A15175 mTOR inhibitormTOR inhibitor is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 1.5 nM. Learn More -
MHY1485
Catalog No. A15508 mTOR inhibitorMHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes. Learn More -
Torin 1
Catalog No. A11587 mTOR inhibitorTorin1 is a potent inhibitor of mTOR with IC50 of 2-10 nM. Learn More -
LY3023414
Catalog No. A16126 PI3K/mTOR Dual InhibitorLY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242). Learn More -
SAR245409 (XL765, Voxtalisib)
Catalog No. A16276 PI3K/mTOR dual inhibitorSAR245409 is a PI3K/mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Learn More -
FT-1518
Catalog No. A19230 mTORC1/mTORC2 inhibitorFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. Learn More -
PI3K/mTOR Inhibitor-2
Catalog No. A19621 dual pan-PI3K/mTOR inhibitorPI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity. Learn More -
mTOR inhibitor-1
Catalog No. A20029 mTOR inhibitormTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy. Learn More -
PI3K/mTOR Inhibitor-1
Catalog No. A20055 PI3K/mTOR inhibitorPI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively. Antitumor activity. Learn More -
PQR620
Catalog No. A20400 mTORC1/2 inhibitorPQR620 is a novel potent and selective brain penetrant inhibitor of mTORC1/2. Learn More -
3BDO
Catalog No. A22360 mTOR activator3BDO is a new mTOR activator which can also inhibit autophagy. Learn More -
BEZ235 (NVP-BEZ235, Dactolisib)
Catalog No. A10133 PI3K/mTOR InhibitorBEZ235 (NVP-BEZ235) inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Learn More -
PP242 (Torkinib)
Catalog No. A10746 mTOR InhibitorPP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2. Learn More -
PF-04691502
Catalog No. A11024 PI3K/mTOR InhibitorPF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway. Learn More -
GDC-0980 (Apitolisib, RG7422)
Catalog No. A11023 mTOR/PI3K InhibitorGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α, β, δ and γ isoforms, respectively. Learn More -
GSK2126458 (Omipalisib)
Catalog No. A11035 mTOR/PI3K Inhibitor,GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Learn More -
Everolimus (RAD001)
Catalog No. A10374 mTOR inhibitorEverolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an mTOR inhibitor. Learn More -
GSK1059615
Catalog No. A10438 mTOR/PI3K InhibitorGSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM). Learn More -
PI-103
Catalog No. A10726 PI3K InhibitorPI-103 is a potent, cell-permeable, ATP-competitive inhibitor of phosphatidylinositol 3-kinase (PI3K) family members with selectivity toward DNA-PK, PI3K (p110α), and mTOR. Learn More -
Rapamycin (Sirolimus)
Catalog No. A10782 mTOR InhibitorsRapamycin (Sirolimus) prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2). Learn More -
PQR-530
Catalog No. A19209 dual pan-PI3K/mTORC1/2 inhibitorPQR-530 is a potent, oral and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, exhibiting antitumor activity. Learn More -
42-(2-Tetrazolyl)rapamycin
Catalog No. A21394 mTOR inhibitor42-(2-Tetrazolyl)rapamycin is a prodrug compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor. Learn More -
HDACs/mTOR Inhibitor 1
Catalog No. A13462 HDACs/mTOR Inhibitor 1HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies. Learn More -
mTOR inhibitor-2
Catalog No. A13035 mTOR inhibitormTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates. Learn More -
Dactolisib Tosylate
Catalog No. A11327 dual PI3K and mTOR kinase inhibitorDactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2. Learn More -
CZ415
Catalog No. A16476 mTOR inhibitorCZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex. Learn More -
Desmethyl-VS-5584
Catalog No. A10900 PI3K/mTOR inhibitorDesmethyl-VS-5584 is a demethyl analogue of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Learn More -
KU-0063794
Catalog No. A10505 mTOR InhibitorKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively). Learn More -
Temsirolimus (Torisel)
Catalog No. A10906 mTOR inhibitorTemsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells. Learn More -
NSC781406
Catalog No. A20402 PI3K/mTOR inhibitorNSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα. Learn More -
CC-223
Catalog No. A13078 mTOR InhibitorCC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K-alpha (IC50=4uM). Learn More -
CC-115
Catalog No. A15779 mTOR/DNA-PK inhibitorCC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM). Learn More -
Palomid 529 (P529)
Catalog No. A10693 AKT InhibitorPalomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation. Learn More -
Zotarolimus
Catalog No. A11950 mTOR inhibitorZotarolimus is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Learn More -
WYE-687
Catalog No. A11187 mTOR InhibitorWYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin(mTOR).
Learn More -
WAY-600
Catalog No. A11188 mTOR inhibitorWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
Learn More -
PP121
Catalog No. A11207 PI3K InhibitorPP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR). Learn More -
NVP-BGT226
Catalog No. A11162 PI3K inhibitorNVP-BGT226, novel phosphoinositide 3-kinase/mTOR dual inhibitor, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Learn More -
Deforolimus (Ridaforolimus)
Catalog No. A10295 mTOR InhibitorDeforolimus (Ridaforolimus) is an investigational targeted and small-molecule inhibitor of the protein mTOR. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.
Learn More -
PKI-587 ( Gedatolisib )
Catalog No. A11079 PI3K/mTOR inhibitorPKI-587 is a highly potent PI3K/mTOR kinase inhibitor that inhibits PI3K-α,β,γ, δ isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively. Learn More -
OSI-027
Catalog No. A11056 mTOR inhibitorOSI-027 is a potent, selective and orally bioavailable mTOR kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR. Learn More -
INK 128 (MLN0128)
Catalog No. A11461 mTOR inhibitorINK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. Learn More -
GDC-0349
Catalog No. A11443 mTOR inhibitorGDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Learn More
Adooq Quality Guarantee
We promise all products perform as described.